

# Systematic Review and Meta-analysis: An Empirical Approach to Defining Treatment Response and Remission in Pediatric Obsessive-Compulsive Disorder

Luis C. Farhat, MD<sup>ID</sup>, Edoardo F.Q. Vattimo, MD<sup>ID</sup>, Divya Ramakrishnan, MD Candidate<sup>ID</sup>, Jessica L.S. Levine, BA, Jessica A. Johnson, DNP, PMHNP, Bekir B. Artukoglu, MD, Angeli Landeros-Weisenberger, MD<sup>ID</sup>, Fernando R. Asbahr, MD, PhD, Sandra L. Cepeda, MS<sup>ID</sup>, Jonathan S. Comer, PhD<sup>ID</sup>, Daniel Fatori, PhD<sup>ID</sup>, Martin E. Franklin, PhD, Jennifer B. Freeman, PhD, Daniel A. Geller, MD<sup>ID</sup>, Paul J. Grant, MD, Wayne K. Goodman, MD, Isobel Heyman, MD, PhD<sup>ID</sup>, Tord Ivarsson, MD, PhD<sup>ID</sup>, Fabian Lenhard, PhD<sup>ID</sup>, Adam B. Lewin, PhD, ABPP, Fenghua Li, PhD<sup>ID</sup>, Lisa J. Merlo, PhD, MPE<sup>ID</sup>, Hamid Mohsenabadi, PhD<sup>ID</sup>, Tara S. Peris, PhD<sup>ID</sup>, John Piacentini, PhD<sup>ID</sup>, Ana I. Rosa-Alcázar, PhD<sup>ID</sup>, Ángel Rosa-Alcázar, PhD<sup>ID</sup>, Michelle Rozenman, PhD<sup>ID</sup>, Jeffrey J. Sapyta, PhD, Eva Serlachius, MD, PhD<sup>ID</sup>, Mohammad J. Shabani, PhD<sup>ID</sup>, Roseli G. Shavitt, MD, PhD<sup>ID</sup>, Brent J. Small, PhD<sup>ID</sup>, Gudmundur Skarphedinsson, PhD<sup>ID</sup>, Susan E. Swedo, MD<sup>ID</sup>, Per Hove Thomsen, MD<sup>ID</sup>, Cynthia Turner, PhD, Bernhard Weidle, MD<sup>ID</sup>, Euripedes C. Miguel, MD, PhD<sup>ID</sup>, Eric A. Storch, PhD<sup>ID</sup>, David Mataix-Cols, PhD<sup>ID</sup>, Michael H. Bloch, MD, MS<sup>ID</sup>

Drs. Farhat and Vattimo contributed equally to this work.

**Objective:** A lack of universal definitions for response and remission in pediatric obsessive-compulsive disorder (OCD) has hampered the comparability of results across trials. To address this problem, we conducted an individual participant data diagnostic test accuracy meta-analysis to evaluate the discriminative ability of the Children's Yale–Brown Obsessive-Compulsive Scale (CY-BOCS) in determining response and remission. We also aimed to generate empirically derived cutoffs on the CY-BOCS for these outcomes.

**Method:** A systematic review of PubMed, PsycINFO, Embase and CENTRAL identified 5,401 references; 42 randomized controlled clinical trials were considered eligible, and 21 provided data for inclusion (N = 1,234). Scores of  $\leq 2$  in the Clinical Global Impressions Improvement and Severity scales were chosen to define response and remission, respectively. A 2-stage, random-effects meta-analysis model was established. The area under the curve (AUC) and the Youden Index were computed to indicate the discriminative ability of the CY-BOCS and to guide for the optimal cutoff, respectively.

**Results:** The CY-BOCS had sufficient discriminative ability to determine response (AUC = 0.89) and remission (AUC = 0.92). The optimal cutoff for response was a  $\geq 35\%$  reduction from baseline to posttreatment (sensitivity = 83.9, 95% CI = 83.7–84.1; specificity = 81.7, 95% CI = 81.5–81.9). The optimal cutoff for remission was a posttreatment raw score of  $\leq 12$  (sensitivity = 82.0, 95% CI = 81.8–82.2; specificity = 84.6, 95% CI = 84.4–84.8).

**Conclusion:** Meta-analysis identified empirically optimal cutoffs on the CY-BOCS to determine response and remission in pediatric OCD randomized controlled clinical trials. Systematic adoption of standardized operational definitions for response and remission will improve comparability across trials for pediatric OCD.

**Key words:** obsessive-compulsive disorder, randomized controlled trials, meta-analysis, diagnostic test accuracy, CY-BOCS

J Am Acad Child Adolesc Psychiatry 2022;61(4):495–507.  

 Obsessive-compulsive disorder (OCD) is a common psychiatric condition among children and adolescents<sup>1,2</sup> that is characterized by intrusive unwanted thoughts or urges (obsessions) and repetitive

behaviors or mental acts (compulsions).<sup>3</sup> The Children's Yale–Brown Obsessive-Compulsive Scale (CY-BOCS) is a semi-structured, clinician-rated instrument that is typically used to evaluate the presence and severity of OCD

symptoms over the past week in youths.<sup>4</sup> It contains two 5-item severity rating scales, one for obsessions and one for compulsions, which are then summed to obtain a total severity score. The CY-BOCS has good psychometric properties<sup>4,5</sup> and has been widely adopted in randomized controlled trials (RCTs) of interventions for pediatric OCD as the instrument of choice to measure OCD symptom severity and change.

Pediatric OCD RCTs have typically determined the improvement in mean CY-BOCS scores from baseline to posttreatment in the active vs the control group as the primary outcome for efficacy. However, the clinical meaning of these average changes in CY-BOCS scores across treatment groups is debatable. It could be argued that reductions in mean CY-BOCS scores are less informative clinically than the likelihood of responding positively to treatment or achieving remission. Several pediatric OCD trials have reported positive treatment response, that is, a substantial improvement in symptoms, and remission, that is, the presence of no more than minimal symptoms, as secondary outcomes. Unfortunately, and similarly to adult OCD studies, definitions of positive treatment response and remission have not been consistent across RCTs for pediatric OCD. For instance, different thresholds of improvement (25%,<sup>6-8</sup> 30%,<sup>9</sup> 40%<sup>10</sup> or 50%<sup>11</sup>) and posttreatment severity (11,<sup>12</sup> 14<sup>13</sup>) based on the CY-BOCS have been adopted to determine positive treatment response and remission, respectively. In addition, a large proportion of clinical researchers in pediatric OCD have adopted only the Clinical Global Impressions–Improvement (CGI-I) and Clinical Global Impression–Severity (CGI-S)<sup>12-15</sup> scales to define positive treatment response and remission, respectively. Solely relying on the CGI-I or CGI-S might be problematic, as improvements in these scales may not be as rigorous as quantitative measures. For instance, improvements in commonly comorbid conditions such as depression, anxiety, and tics may also be combined with improvement in OCD symptoms when using more general scales of improvement or severity.

Importantly, the lack of consistency in reporting criteria for positive treatment response and remission in pediatric OCD RCTs has created challenges when comparing rates across trials, that is, in meta-analyses, and as a result, communication in the field has been stunted. In an attempt to address this issue, Mataix-Cols *et al.*<sup>16</sup> conducted a multi-round, Web-based Delphi survey involving international experts to provide a consensus definition of positive treatment response and remission in OCD. The consensus determined as the operational definitions of (1) positive treatment response a  $\geq 35\%$  reduction in (C)-YBOCS scores plus a CGI-I  $\leq 2$  and of (2) remission a (C)-YBOCS

score  $\leq 12$  plus a CGI-S  $\leq 2$ ; both were required to last for at least 1 week.

However, there have been few studies using empirical methods to validate such operational criteria. In pediatric populations, 2 studies have examined, through signal detection analyses, the optimal amount of symptom improvement and severity to classify an individual as a “positive responder” and “remitter,” but conflicting findings have been reported.<sup>17,18</sup> Specifically, both 25% and 35% reductions have been identified as the minimal improvement required to determine positive treatment response; likewise, both 14 and 11 posttreatment scores have been identified as the maximum severity required to determine remission. These inconsistencies may be explained, at least in part, by limited statistical power, particularly for remission, a relatively rare outcome. Available evidence<sup>19</sup> indicates that a sample size of at least 775 individuals would be required to perform diagnostic accuracy analysis with a sufficient level of power (80%) and a low level of type I error (0.05). Because previous studies analyzed data from a considerably smaller set of participants (N = 109; 269), additional research with larger samples is currently warranted.

To address this gap, we conducted an individual participant data (IPD) diagnostic test accuracy (DTA) meta-analysis to determine the empirically optimal (1) percent and absolute reductions in CY-BOCS scores from baseline to posttreatment that correspond to positive treatment response; and the (2) posttreatment CY-BOCS raw score that corresponds to remission. This article is written in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The PRISMA checklist<sup>20,21</sup> can be found in Supplement 1, available online. A protocol was not established for this review. Our group is currently working on a similar effort for the Y-BOCS, the adult scale, but its data has not yet been published.

## METHOD

### Eligibility Criteria

References were considered eligible for inclusion in the meta-analysis if the study (a) included individuals  $\leq 18$  years of age with a diagnosis of OCD as determined through formal diagnostic criteria (eg, *DSM-III*, *DSM-III-R*, *DSM-IV*, *DSM-IV-TR*, *DSM-5*, *ICD-9*, *ICD-10*); (b) evaluated the efficacy of any pharmacological or psychotherapeutic interventions in comparison to any control condition in the short-term ( $\sim 1$ -4 months) using random allocation procedures to determine the treatment group for participants. Studies including individuals who were considered to be “treatment resistant” or “treatment refractory” were

considered eligible. Pharmacological interventions were required to be orally administered to be considered eligible. Add-on pharmacological and multimodal treatment studies, that is, combinations of medication and psychotherapy such as D-cycloserine—augmented cognitive-behavioral therapy (CBT) or selective serotonin reuptake inhibitors combined with CBT, were considered eligible. Studies with passive control conditions, such as community treatment/treatment as usual and wait-list, were eligible for inclusion. Studies including individuals who had an abrupt onset of obsessive-compulsive symptoms, such as those fulfilling criteria for pediatric acute-onset neuropsychiatric syndrome (PANS), were not considered eligible. Cross-over studies were not eligible so as to avoid including 2 sets of observations for the same individual. Studies that randomized fewer than 10 participants were not considered eligible.

### Study Identification and Selection Process

Selected electronic databases (PubMed, CENTRAL, EMBASE and PsycINFO) were searched from inception to March to July 2020 for relevant references. Search strategies were tailored for each database, and detailed descriptions can be found in Supplement 2, available online. The references section of review articles and meta-analyses were carefully read to identify additional eligible studies. No language restrictions were applied. No further efforts were made to search for unpublished research. Titles and abstracts of records were screened by 2 independent reviewers (LCF, DR) to identify those that were eligible for inclusion. Disagreements between the 2 reviewers were solved through discussion with a third independent reviewer (MHB). Risk of bias of individual studies was not assessed.

### Data Collection and Data Items

An e-mail message was sent to either the first or last author of articles fulfilling the eligibility criteria for our meta-analysis. If authors failed to reply to our first e-mail, follow-ups were sent at least 1 week after the first e-mail. We also tried to contact other study coauthors if we did not receive a reply to the initial e-mail.

Individual participant data were requested for the following: (1) CY-BOCS total score at baseline, (2) CY-BOCS total score at posttreatment, (3) CGI-I scores at posttreatment, (4) CGI-S scores at posttreatment, and (5) treatment group to which the individual was allocated.

### Diagnostic Test Accuracy Meta-analytical Method

We evaluated CY-BOCS percent and absolute reductions from baseline to posttreatment in relation to positive treatment response.<sup>16</sup> Cutoffs on the CY-BOCS were

calculated at every 5%, from 5% to 70%, for percent reductions<sup>17,18</sup> and at every 2 points, from 2 to 28, for absolute reductions. Positive treatment response was conceptually defined as a clinically meaningful reduction in symptoms relative to baseline severity. A CGI-I score of either 2 (“much improved”) or 1 (“very much improved”) was adopted as the primary operational definition of positive treatment response. A 10-point reduction on the CY-BOCS based on a Reliable Change Index (RCI) of  $\geq 1.96$ <sup>22</sup> (details on this metric and its calculation can be found in Supplement 2, available online) was used as a secondary operational definition of positive treatment response for percent reductions as sensitivity analysis.

We evaluated CY-BOCS posttreatment raw scores in relation to remission.<sup>16</sup> Cutoffs on the CY-BOCS were calculated at every 1-point, from 5 to 20, for raw score severity.<sup>17,18</sup> Remission was conceptually defined as an individual having no more than minimal symptoms. A CGI-S score of either 2 (“borderline mentally ill”) or 1 (“normal, not at all ill”) was adopted as the operational definition of remission.

Because each study contributed with multiple data points to the meta-analysis, we established a 2-stage random effects meta-analysis model for multiple thresholds.<sup>23</sup> At the study-level, 1-sensitivity values at all thresholds provide an estimate of the cumulative distribution function (CDF) of the CY-BOCS reductions/raw scores for positive responders/remitters. Likewise, specificity values at all thresholds provide an estimate of the CDF of the CY-BOCS reductions/raw scores for non-positive responders/nonremitters. At the meta-analytical level, the model fits the data for positive responders/remitters, non-positive responders/nonremitters, and all available thresholds, providing estimates of the CDF for each group across all studies. A logit transformation to 1-sensitivity/specificity values is adopted to fit a linear model. We adopted a random intercept model to fit the data and assumed equal variances in the distribution of the CY-BOCS among positive responders/remitters and non-positive responders/nonremitters. Each data point was weighted by the inverse variance. All analyses were conducted in R using the package “diagmeta.”<sup>24</sup> To increase the reproducibility of our research, we have made all code available online in OSF (<https://DOI:10.17605/OSF.IO/U5DRX>).

We obtained pooled sensitivity and specificity with 95% CIs for every CY-BOCS cutoff for response and remission. Pooled values of sensitivity and specificity were used to plot summary receiver operating characteristic (SROC) curves. The area under the SROC Curve (AUC) was computed to indicate the discriminative ability of the CY-BOCS in determining positive treatment response and

remission; values range from 0.5, indicating no discriminative ability, to 1, corresponding to perfect discrimination. We also used pooled values of accuracy measures to calculate the Youden Index (*J*), which was used to help inform the optimal cutoff. The *J* statistic is computed by the maximum value of the difference between sensitivity and 1-specificity and represents the maximum vertical distance from the SROC curve to the chance line.<sup>25</sup>

The *I*<sup>2</sup> statistic typically used to assess heterogeneity is not useful in DTA meta-analyses because it does not account for the correlation between sensitivity and specificity. Therefore, heterogeneity was evaluated by visual inspection of the confidence ellipse in the SROC curve, which indicates the uncertainty around the optimal cutoff.<sup>26</sup> We did not evaluate publication bias, because this is not routinely recommended in DTA meta-analyses.<sup>27</sup>

**RESULTS**


**Study Selection and IPD Obtained**

Our search identified 5,401 references, of which 42 RCTs were considered eligible for inclusion.<sup>6-15,28-59</sup> Figure 1 depicts the PRISMA flowchart for the inclusion/exclusion procedures with reasons for exclusion. Of the 42 potentially eligible trials, 4 authors replied that they did not have the CGI-I/CGI-S in their assessments. Of the remaining 38 studies, we were able to obtain IPD for 21 (55.26%)

studies.<sup>6,9,11-14,34,38-44,47,51,52,54-57</sup> Reasons for which we were unable to obtain IPD from trials were lack of access (9), refusal to share data due to institutional review board restrictions, (2) and lack of response to our request (6).

**Study Characteristics**

Table 1 depicts the characteristics of the included studies. Of the 21 included studies, 14 (67%) recruited participants from North America, 4 (19%) from Europe, 2 (9%) from South America, and 1 (5%) from Asia. Across the 21 RCTs, a total of 1,234 participants whose mean age was 12 years (SD = 4) were included; 716 (58%) were boys. Fifteen studies (71%), including 13 (93%) from the United States, reported the race/ethnicity of participants; of the 876 participants with race/ethnicity information, 764 (87%) self-identified as White. Select studies included between 1% and 3% of African American/Black individuals; between 1% and 7% of Asian American individuals; and between 2% and 13% of Hispanic/Latino individuals. In total, of the 1,234 participants, 223 (18%), 650 (53%), and 298 (24%) were enrolled in a pharmacological, psychotherapeutic, and multimodal treatment arm, respectively. The remaining 63 participants (5%) were enrolled in passive control conditions. The mean study sample size was 59 (SD = 36). The mean year of publication was 2013 (SD = 4). None of the 21 studies were funded by pharmaceutical companies.



**TABLE 1** Characteristics of Included Studies

First author, year, reference	Country	Age <sup>a</sup>	Sex <sup>b</sup>	Race/ethnicity <sup>c</sup>	Treatment arms	N	Endpoint <sup>d</sup>	Outcomes	Funding
Asbahr, 2005 <sup>6</sup>	BR	13.1 (2.6)	65	Not reported	SSRI; GCBT	40	12	CGI-S	FAPESP
Comer, 2017 <sup>34</sup>	US	6.7 (1.3)	59	91	FB-CBT; VTC-FB-CBT	22	14	CGI-S; CGI-I	IOCDF/NIH
Fatori, 2018 <sup>11</sup>	BR	11.8 (3.2)	48	92	SSRI; GCBT	83	14	CGI-I	FAPESP
Franklin, 2011 <sup>38</sup>	US	13.6 (2.8)	47	93	SRI; SRI + CBT; SRI + iCBT	124	12	CGI-S; CGI-I	NIMH
Freeman, 2008 <sup>39</sup>	US	7.1 (1.3)	43	80	FB-CBT; FB-RT	42	14	CGI-I	NIMH
Freeman, 2014 <sup>40</sup>	US	7.2 (1.2)	47	90	FB-CBT; FB-RT	127	14	CGI-S; CGI-I	NIMH
Grant, 2014 <sup>41</sup>	US	14.5 (2.4)	73	Not reported	Riluzole; placebo	60	12	CGI-S; CGI-I	IP-NIMH
Lenhard, 2017 <sup>42</sup>	SE	14.6 (1.7)	54	Not reported	Internet-based CBT; WL	67	12	CGI-S; CGI-I	SRC/SCC
Lewin, 2014 <sup>43</sup>	US	5.8 (1.6)	71	87	CBT; Treatment as usual	31	6	CGI-S; CGI-I	USFRC
Li, 2020 <sup>44</sup>	US	11.9 (2.9)	73	100	N-acetyl cysteine; placebo	11	6	CGI-S; CGI-I	BBRF
Merlo, 2010 <sup>47</sup>	US	13.3 (3.0)	63	81	MI + CBT; PE + CBT	16	3	CGI-S; CGI-I	Not reported
Peris, 2017 <sup>13</sup>	US	13.1 (2.7)	56	65	PFIT + CBT; ST + CBT	62	12	CGI-I	BBRF/NIMH
Piacentini, 2011 <sup>12</sup>	US	12.2 (2.5)	37	78	FCBT; PRT	71	14	CGI-S; CGI-I	NIMH
Rosa-Álcazar, 2019 <sup>51</sup>	ES	6.6 (0.7)	75	100	Parent CBT; parent + child CBT	44	12	CGI-S; CGI-I	MEC
Shabani, 2019 <sup>52</sup>	IR	15.0 (1.5)	55	Not reported	SSRI + ACT; SSRI + CBT; SSRI	69	10/ 12	CGI-S; CGI-I	KUMS
Skarphedinsson, 2015 <sup>9</sup>	DE/NO/SE	14.0 (2.7)	48	Not reported	SSRI; CBT	50	16	CGI-S; CGI-I	Multiple
Storch, 2007 <sup>55</sup>	US	13.3 (2.7)	45	92	Intensive CBT; weekly CBT	40	3/ 14	CGI-S; CGI-I	Not reported
Storch, 2010 <sup>56</sup>	US	12.2 (2.8)	63	97	DCS + CBT; placebo + CBT	30	8	CGI-S; CGI-I	BBRF/NIMH
Storch, 2011 <sup>54</sup>	US	11.1 (2.6)	61	74	CBT via web-camera; WL	31	12	CGI-S; CGI-I	FMHI
Storch, 2016 <sup>14</sup>	US	12.8 (3.0)	46	88	DCS + CBT; placebo + CBT	142	8	CGI-S; CGI-I	NIMH
Turner, 2014 <sup>57</sup>	GB	14.3 (2.1)	54	Not reported	Telephone-based CBT; CBT	72	17	CGI-S; CGI-I	NIHR

**Note:** ACT = acceptance-commitment therapy; BBRF = Brain & Behavior Research Foundation; CBT = cognitive-behavioral therapy; DCS = D-cycloserine; FAPESP = Fundação de Amparo à Pesquisa do Estado de São Paulo; FB-CBT = family-based cognitive-behavioral therapy; FB-RT = family-based relaxation training; FCBT = child CBT plus family intervention; FMHI = Florida Mental Health Institute; GCBT = group cognitive-behavioral therapy; iCBT = instructions in CBT; IOCDF = International Obsessive-Compulsive Disorder Foundation; IP-NIMH = Intramural program of the National Institute of Mental Health; KUMS = Kashan University of Medical Science; MEC = Ministerio de Economía y Competividad del Gobierno de España; MI = motivational interviewing; Multiple = TrygFonden, the Danish Council for Strategic Research, Pulje til styrkelse af psykiatrisk forskning i Region Midtjylland, The Center for Child and Adolescent Mental Health, Eastern and Southern Norway (RBUP), Stiftelsen Clas Groschinskys Minnesfond, Stiftelsen Clas Groschinskys Minnesfond; NIH = National Institutes of Health; NIHR = National Institute for Health Research; NIMH = National Institute of Mental Health; PE = psychoeducation; PFIT = positive family interaction therapy; PRT = psychoeducation/relaxation training; SCC = Stockholm County Council; SRC = Swedish Research Council; SRI = serotonin reuptake inhibitor; ST = standard treatment; SSRI = selective serotonin reuptake inhibitor; USFRC = University of South Florida Research Counsel; VTC-FB-CBT = videoteleconferencing family-based cognitive-behavioral therapy.

<sup>a</sup>Mean and standard deviation.

<sup>b</sup>Percentage of male participants.

<sup>c</sup>Percentage of individuals who self-identified as White.


<sup>d</sup>Weeks.

Table S1, available online, lists characteristics of the 21 studies that were eligible but that did not provide IPD for inclusion in the meta-analysis. Although the majority of these studies recruited participants from North America (48%), a larger proportion recruited participants from Europe (33%), Oceania (9%), and Asia (10%). Across the 21 RCTs, 1,381 participants whose mean age was 12 years (SD = 3) were included; 603 (53%) were boys. The majority of participants (810 [59%]) were allocated to a pharmacological treatment arm, whereas substantially

smaller proportions were allocated to a psychotherapeutic (300 [22%]) or multimodal (124 [9%]) treatment arm. The mean study sample size was 66 (SD = 54). The mean year of publication was 2006 (SD = 6). Six of the 15 studies with funding information available (40%) were supported by pharmaceutical companies.

After excluding individuals who dropped out before the posttreatment assessment, 1,092 and 948 participants were retained for the meta-analysis for positive treatment response and remission, respectively.

**FIGURE 2** Children’s Yale–Brown Obsessive-Compulsive Scale Percent Reduction Cutoffs and Positive Treatment Response as Defined by the Clinical Global Impressions–Improvement Scale Score of  $\leq 2$



**Note:** The top panel shows the summary receiver operating characteristics (SROC) curve, which demonstrates the overall performance of the Children’s Yale–Brown Obsessive-Compulsive Scale (CY-BOCS). Points were colored at the study level. Confidence intervals for pooled sensitivity (solid) and specificity (dash) estimates are also illustrated. Both 35% and 40% reduction cutoffs were comprised by the ellipse, which indicates the uncertainty around the optimal cutoff. The lower left panel shows the trade-offs between pooled sensitivity (solid) and specificity (dash) estimates for each percent reduction cutoff. The 35% reduction cutoff displayed adequate sensitivity and specificity. The lower right panel shows the Youden Index, a statistic that maximizes both sensitivity and specificity, for each cutoff. The 35% reduction cutoff was found to maximize accuracy measures according to the Youden Index.

**Positive Treatment Response**

The meta-analysis indicated that percent reductions from baseline to posttreatment had sufficient discriminative ability (AUC = 0.89) to determine positive treatment response as defined by the CGI-I, our primary operational definition of positive treatment response. There was slight uncertainty regarding the confidence around the optimal cutoff because both the 35% and 40% reduction cutoffs were comprised by the ellipse according to visual inspection of the SROC curve (Figure 2, top panel). The Youden Index indicated that a ≥35% reduction in CY-BOCS from baseline to posttreatment was optimal to determine positive treatment response as defined by the CGI-I (Figure 2, lower panels). The 35% reduction cutoff had a sensitivity of 83.9% (95% CI = 83.7–84.1) and a specificity of 81.7% (95% CI = 81.5–81.9) (Table 2).

The meta-analysis also indicated that absolute reductions from baseline to posttreatment had sufficient discriminative ability (AUC = 0.83) to determine positive treatment response as defined by the CGI-I. There was slight uncertainty regarding the confidence around the optimal cutoff because both the 8-point and 10-point cutoffs were comprised by the ellipse according to visual inspection of the SROC curve (see Figure S1, top panel, available online). The Youden Index indicated that a ≥10-point reduction in CY-BOCS from baseline to posttreatment was optimal to determine positive treatment response as defined by the CGI-I (see Figure S1, lower panels, available online). The 10-point reduction cutoff had a sensitivity of 75.8% (95% CI = 75.5–76.0) and a specificity of 77.8% (95% CI = 77.6–78.1) (see Table S2, available online).

The meta-analysis also indicated that percent reductions from baseline to posttreatment had sufficient discriminative ability (AUC = 0.92) to determine positive treatment response as defined by the RCI, our secondary operational definition of positive treatment response. There was more certainty regarding the confidence around the optimal cutoff because only the 40% reduction cutoff was comprised by the ellipse according to visual inspection of the SROC curve (see Figure S2, top panel, available online). The Youden Index indicated that a ≥40% reduction in CY-BOCS from baseline to posttreatment was optimal to determine positive treatment response as defined by the RCI (see Figure S2, lower panels, available online). The 40% reduction cutoff had a sensitivity of 86.0% (95% CI = 85.8–86.1) and a specificity of 86.1% (95% CI = 85.9–86.3) (see Table S3, available online).

**Remission**

The meta-analysis indicated that the posttreatment raw scores had sufficient discriminative ability (AUC = 0.90) to determine remission as defined by the CGI-S. There was some uncertainty regarding the confidence around the optimal cutoff because the 11, 12, and 13 raw score cutoffs were all comprised by the ellipse according to visual inspection of the SROC curve (Figure 3, top panel). The Youden Index indicated that a posttreatment raw score of ≤12 in CY-BOCS was optimal to determine remission as defined by the CGI-S (Figure 3, lower panels). The 12-point cutoff had a sensitivity of 82.0% (95% CI = 81.8–82.2) and a specificity of 84.6% (95% CI = 84.4–84.8) (Table 3).

**TABLE 2** Accuracy Measures of Children’s Yale–Brown Obsessive-Compulsive Scale Percent Reductions for Response According to a Clinical Global Impressions–Improvement Score ≤2

Cutoffs (%)	Sens (%)	95% CI (%)	Spec (%)	95% CI (%)	J <sup>a</sup>	95% CI
5	98.0	97.9-98.0	32.7	32.4-33.0	30.6	30.3-30.9
10	97.1	97.0-97.1	41.3	40.9-41.6	38.3	38.0-38.7
15	95.8	95.8-95.9	50.4	50.1-50.7	46.2	45.9-46.6
20	94.1	94.0-94.1	59.6	59.2-59.9	53.6	53.2-54.0
25	91.6	91.5-91.7	68.1	67.8-68.4	59.7	59.3-60.1
30	88.3	88.2-88.4	75.5	75.3-75.8	63.8	63.5-64.2
<b>35</b>	<b>83.9</b>	<b>83.7-84.1</b>	<b>81.7</b>	<b>81.5-81.9</b>	<b>65.6</b>	<b>65.3-66.0</b>
40	78.3	78.0-78.5	86.6	86.5-86.8	64.9	64.5-65.3
45	71.3	71.1-71.6	90.4	90.2-90.5	61.7	61.3-62.0
50	63.2	62.9-63.5	93.1	93.0-93.2	56.3	55.9-56.7
55	54.2	53.9-54.6	95.2	95.1-95.2	49.4	49.0-49.8
60	45.0	44.7-45.3	96.6	96.6-96.7	41.6	41.3-42.0
65	36.1	35.8-36.4	97.6	97.6-97.7	33.7	33.4-34.1
70	28.1	27.8-28.4	98.4	98.3-98.4	26.4	26.2-26.7


Note: Boldface type indicates optimal cutoff. Sens = sensitivity; Spec = specificity.  
<sup>a</sup>Youden index.

**DISCUSSION**

We performed an IPD meta-analysis to evaluate the discriminative ability of the CY-BOCS in determining positive treatment response and remission in RCTs for pediatric OCD. We also determined the empirically optimal cutoffs corresponding to both of these outcomes. Meta-analyses indicated that the percent (AUC = 0.89) and absolute (AUC = 0.83) reductions from baseline to

posttreatment had sufficient discriminative ability to determine positive treatment response as defined by the CGI-I of  $\leq 2$ ; the percent reductions also had sufficient discriminative ability (AUC = 0.92) to determine positive treatment response as defined by the RCI of  $\geq 1.96$ . For percent reductions, both  $\geq 35\%$  (CGI-I) and  $\geq 40\%$  (RCI) reductions were identified as optimal; for absolute reductions, a  $\geq 10$ -point reduction was identified as optimal.

**FIGURE 3** Children’s Yale–Brown Obsessive–Compulsive Scale Raw Score Cutoffs and Remission as Defined by the Clinical Global Impressions–Severity Scale Score of  $\leq 2$



**Note:** The top panel shows the summary receiver operating characteristics (SROC) curve, which demonstrates the overall performance of the Children’s Yale–Brown Obsessive–Compulsive Scale. Points were colored at the study level. Confidence intervals for pooled sensitivity (solid) and specificity (dash) estimates are also illustrated. The 11, 12, and 13 raw score cutoffs were comprised by the ellipse, which indicates the uncertainty around the optimal cutoff. The lower left panel shows the trade-offs between pooled sensitivity (solid) and specificity (dash) estimates for each raw score cutoff. The 12-point cutoff displayed adequate sensitivity and specificity. The lower right panel shows the Youden Index, a statistic that maximizes both sensitivity and specificity, for each cutoff. The 12-point cutoff was found to maximize accuracy measures according to the Youden Index. Please note color figures are available online.

Meta-analysis indicated the posttreatment raw scores had sufficient discriminative ability (AUC = 0.90) to determine remission as defined by the CGI-S of  $\leq 2$ . A posttreatment raw score of  $\leq 12$  was identified as optimal.

Meta-analyses suggested that percent reductions have slightly larger discriminative ability than absolute reductions in determining positive treatment response, and therefore, the former should be preferred above the latter. Regarding the optimal threshold for percent reductions, both  $\geq 35\%$  (CGI-I) and  $\geq 40\%$  (RCI) reductions have been found to be optimal depending on the criterion adopted to define positive treatment response. Given that the CGI-I represents the clinician’s judgment of overall improvement whereas the RCI simply indicates that the reliable change is unlikely to be attributed to measurement error alone, we believe that the available evidence provides a more compelling case to adopt the 35% reduction cutoff, a strong indicator of positive treatment response, in future RCTs for pediatric OCD. In addition, the percent reductions are intertwined with scale-standardized metrics such as the RCI; for instance, for every participant with a baseline score of  $\leq 25$ , a 10-point reduction always corresponds to a  $\geq 40\%$  reduction in the CY-BOCS. This could have artificially inflated the accuracy measures of the CY-BOCS and of certain cutoffs when the RCI was adopted to define positive treatment response.

Because, strikingly, our empirically derived findings are nearly identical to the expert-based guidelines,<sup>16</sup> we

recommend that future RCTs adopt a  $\geq 35\%$  reduction from baseline to posttreatment to determine positive treatment response and a posttreatment raw score of  $\leq 12$  to determine remission. Although adopting the CY-BOCS to determine positive treatment response and remission requires dichotomization of a continuous variable, which decreases power,<sup>60,61</sup> from a statistical perspective it eliminates the need for the linearity assumption and makes data summarization more efficient.<sup>62</sup> Adopting a clear definition of positive treatment response and remission in pediatric OCD through the CY-BOCS also aids in clinical practice by making dichotomous outcome results interpretable with regard to a specific magnitude of improvement on the CY-BOCS in individual patients.

Although the present study is able to confirm the adequate discriminative ability of the CY-BOCS in determining positive treatment response and remission and to identify empirically optimal cutoffs for these outcomes, there are potential limitations of the CY-BOCS in measuring these outcomes that have to be disclosed. Exclusively relying on percent reductions and raw scores to determine positive treatment response and remission may be problematic, as these do not take into account the clinician’s judgment regarding global improvement or severity.<sup>63</sup> For instance, children with greater OCD severity may have more room for improvement in the CY-BOCS and therefore might meet a 35% reduction in CY-BOCS during treatment without achieving a clinically meaningful

**TABLE 3** Accuracy Measures of Children’s Yale–Brown Obsessive-Compulsive Scale Raw Scores for Remission According to a Clinical Global Impressions–Severity Score of  $\leq 2$

Cutoffs (%)	Sens (%)	95% CI (%)	Spec (%)	95% CI (%)	J <sup>a</sup>	95% CI
5	34.4	34.0-34.7	98.0	97.9-98.0	32.3	31.9-32.7
6	41.6	41.2-42.0	97.2	97.2-97.3	38.9	38.4-39.3
7	49.3	48.9-49.7	96.3	96.2-96.3	45.5	45.1-46.0
8	57.0	56.6-57.3	95.0	94.9-95.1	51.9	51.5-52.4
9	64.3	64.0-64.7	93.3	93.2-93.4	57.6	57.2-58.1
10	71.1	70.7-71.4	91.1	91.0-91.2	62.1	61.7-62.6
11	77.0	76.7-77.3	88.2	88.1-88.4	65.2	64.8-65.6
<b>12</b>	<b>82.0</b>	<b>81.8-82.2</b>	<b>84.6</b>	<b>84.4-84.8</b>	<b>66.6</b>	<b>66.2-67.1</b>
13	86.1	85.9-86.3	80.2	79.9-80.4	66.3	65.9-66.7
14	89.4	89.3-89.6	74.8	74.5-75.1	64.2	63.8-64.6
15	92.0	91.9-92.1	68.5	68.2-68.9	60.5	60.1-61.0
16	94.0	93.9-94.1	61.5	61.2-61.9	55.5	55.1-56.0
17	95.5	95.5-95.6	54.0	53.6-54.4	49.5	49.1-50.0
18	96.7	96.6-96.7	46.3	45.9-46.6	43.0	42.5-43.4
19	97.5	97.5-97.6	38.7	38.4-39.1	36.3	35.9-36.7
20	98.2	98.2-98.2	31.7	31.4-32.0	29.9	29.5-30.2

Note: Boldface type indicates optimal cutoff. Sens = sensitivity; Spec = specificity.  
<sup>a</sup>Youden Index.

reduction in symptom levels. Similarly, children with lower OCD severity may have less room to improve in the CY-BOCS and might meet a 12-point posttreatment CY-BOCS score without showing minimal symptoms in comparison to the baseline assessment. Indeed, the expert-based guideline<sup>16</sup> further recommends that the CGI-I/CGI-S be employed as necessary auxiliary measures beside the established CY-BOCS cutoffs to determine positive treatment response/remission in pediatric OCD.

Moreover, the CY-BOCS is anchored in the past week. Therefore, adopting this scale to determine positive treatment response/remission corresponds to defining these outcomes based on the severity of OCD symptoms over a 1-week period. Given that OCD typically presents with a “wax and wane” course of symptoms, it seems advisable that larger periods of sustained improvement (~1 month) should be experienced before declaring an individual as a “positive responder” or “remitter.” Indeed, in the expert-based guideline,<sup>16</sup> the majority of experts (56% for positive response, 58% for remission) considered 1 month as the required period to determine positive treatment response and remission among individuals with OCD. However, because the CY-BOCS was developed and validated to measure OCD symptoms over the past week, clinical-researchers would ideally be required to extend follow-up periods for an additional month after the posttreatment assessment to measure OCD symptoms for 4 consecutive weeks. Alternatives to this approach would be to evaluate the validity and stability of the “positive responders” and “remitters” as based on a single posttreatment CY-BOCS score over a longer period of follow-up (eg, 1 month), or to develop and validate a version of the scale that would measure OCD symptoms over 1 month instead of 1 week. To date, this important problem has yet to be adequately explored, and additional research is required.

This study has several strengths. We were able to collect IPD from multiple sites around the world, demonstrating the importance of collaborative cross-site research; to include a sample size at least 4 times larger than those included by the 2 previous studies on the topic, increasing the statistical power of our analyses<sup>19</sup>; to adopt a rigorous systematic review and DTA meta-analysis methodology; and to provide open access to our scripts, hopefully aiding future replication/follow-up studies on the topic. The limitations of this study should also be noted. We included IPD for only 50% of the RCTs for pediatric OCD that were considered eligible in our systematic review of the literature. Although there were not

large discrepancies in sociodemographic characteristics of participants from included vs nonincluded studies, nonincluded RCTs more frequently recruited participants from continents other than the Americas, enrolled participants to pharmacological treatment arms, had larger sample sizes, were older, and received funding from pharmaceutical companies. Multiple factors can help to explain why data acquisition for pharmacological trials was suboptimal, but perhaps most important is the fact that the pharmacological RCTs for pediatric OCD date about 15 to 20 years ago<sup>7,8,10,64</sup>; of note, it is also difficult to acquire individual-level participant information from industry, given the bureaucracy and obstacles to obtaining these data. Regardless, we cannot discard the hypothesis that results could have been modified if a larger proportion of data from eligible studies had been included.<sup>65</sup> The samples included in each RCT were predominantly composed of individuals of White race/ethnicity, indicating that additional efforts are required to increase racial/ethnic diversity among participants in RCTs for pediatric OCD; as a consequence, it is possible, albeit unlikely, that the findings from this study are not generalizable to racial/ethnic minorities such as African American/Black, Asian American, and Hispanic/Latino individuals. Although our study was adequately powered, the sample size was still not large enough to enable the estimation of multiple models with a larger number of parameters; it is possible that more complex models (eg, random intercepts, random slopes) would provide a better fit to the data.

In conclusion, this study provides strong empirical support for the discriminative ability of the CY-BOCS in determining positive treatment response and remission in pediatric OCD RCTs. Empirically derived cutoffs for these outcomes have also been determined. Specifically, a  $\geq 35\%$  reduction from baseline to posttreatment and a posttreatment raw score of  $\leq 12$  should be adopted by future RCTs of interventions for youths with OCD to determine positive treatment response and remission, respectively. Considering percent reductions and raw scores do not take into account the clinician’s judgment regarding global improvement or severity; in instances when CGI data are also available from the same participants, we further suggest that a combination of CY-BOCS and CGI scores be used. Also, additional research is required to investigate the validity and stability of “positive responders” and “remitters” as based on a single posttreatment CY-BOCS score over a longer period of follow-up (eg, 1 month), considering the “wax and wane” pattern of OCD symptoms.

Accepted September 21, 2021.

Drs. Farhat, Vattimo, Asbahr, Fatori, Shavitt and Miguel are with Faculdade de Medicina FMUSP, Universidade de São Paulo, Brazil. Mss. Ramakrishnan, Levine, Drs. Li, Landeros-Weisenberger, and Bloch are with the Yale Child Study Center, Yale School of Medicine, New Haven, Connecticut. Ms. Johnson is with Columbia University New York, and Columbia School of Nursing, New York. Dr. Artukoglu is with SUNY Downstate Health Sciences University, New York. Ms. Cepeda, Drs. Goodman and Storch are with Baylor College of Medicine, Texas. Dr. Comer is with the Center for Children and Families, Florida International University, Miami, Florida. Dr. Franklin is with University of Pennsylvania, Philadelphia, and the Rogers Memorial Hospital, Oconomowoc, Wisconsin. Dr. Freeman is with Warren Alpert Medical School, Brown University, Providence, Rhode Island. Dr. Geller is with Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Dr. Grant is retired, Washington, DC. Dr. Heyman is with the Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom. Drs. Ivarsson, Thomsen and Weidle are with the Regional Center for Child and Youth Mental Health and Child Welfare, Faculty of Medicine and Health Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. Dr. Thomsen is also with the Aarhus University Hospital, Skejby, Denmark. Dr. Weidle is also with the St. Olav's University Hospital, Trondheim, Norway. Drs. Lenhard, Serlachius, and Mataix-Cols are with the Centre for Psychiatry Research, Karolinska Institutet, and with the Stockholm Health Care Services, Region Stockholm, Sweden. Dr. Lewin is with University of South Florida, Hillsborough County. Dr. Merlo is with the University of Florida, Miami. Drs. Mohsenabadi and Shabani are with the Tehran Institute of Psychiatry, Iran University of Medical Sciences, Tehran, IR. Drs. Peris and Piacentini are with the Semel Institute for Neuroscience and Human Behavior, University of California at Los Angeles. Drs. A.I. Rosa-Alcázar and Dr. A. Rosa-Alcázar are with the University of Murcia, Spain. Dr. Rozenman is with University of Denver, Colorado. Dr. Sapyta is with Duke University School of Medicine, Durham, North Carolina. Dr. Small is with the School of Aging Studies, University of South Florida, Hillsborough County. Dr. Skarphedinsson is with the Faculty of Psychology, University of Iceland, Reykjavik. At the time of the study, Dr. Swedo was with the National Institutes of Health, Bethesda, Maryland, and is currently retired. Dr. Turner is with the Primary Care Clinical Unit, Faculty of Medicine, The University of Queensland, Brisbane, Australia.

The authors have reported no funding for this work.

#### Author Contributions

**Conceptualization:** Farhat, Mataix-Cols, Bloch

**Data curation:** Farhat, Vattimo, Ramakrishnan, Levine, Johnson, Artukoglu, Landeros-Weisenberger, Li, Bloch

**Formal analysis:** Farhat, Bloch

**Methodology:** Ramakrishnan, Bloch

**Resources:** Asbahr, Cepeda, Comer, Fatori, Franklin, Freeman, Geller, Grant, Goodman, Heyman, Ivarsson, Lenhard, Lewin, Li, Merlo, Mohsenabadi, Peris, Piacentini, A.I. Rosa-Alcázar, A. Rosa-Alcázar, Rozenman, Sapyta, Serlachius, Shabani, Shavitt, Small, Skarphedinsson, Swedo, Thomsen, Turner, Weidle, Miguel, Storch, Mataix-Cols

**Supervision:** Bloch

**Writing – original draft:** Farhat, Mataix-Cols, Bloch

**Writing – review and editing:** Farhat, Vattimo, Ramakrishnan, Levine, Johnson, Artukoglu, Landeros-Weisenberger, Asbahr, Cepeda, Comer, Fatori, Franklin, Freeman, Geller, Grant, Goodman, Heyman, Ivarsson, Lenhard, Lewin, Li, Merlo, Mohsenabadi, Peris, Piacentini, A.I. Rosa-Alcázar, A. Rosa-Alcázar, Rozenman, Sapyta, Serlachius, Shabani, Shavitt, Small, Skarphedinsson, Swedo, Thomsen, Turner, Weidle, Miguel, Storch, Mataix-Cols, Bloch

**Disclosure:** Dr. Farhat has received salary support from 21/08540-0 by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Dr. Vattimo has reported that he will receive publishing honoraria from Conectfarma on behalf of Aché Laboratórios Farmacêuticos. Dr. Comer has received grant funding from the National Institutes of Health (NIH; R01 HD084497 and R42 MH123368), the Patient-Centered Outcomes Research Institute (PCORI), Boston Medical Center (PCS-2017C2-7588), the National Science Foundation (NSF; 1805645), the Substance Abuse and Mental Health Services Administration (SAMHSA; H79 SM085097), the Andrew Kukes Foundation for Social Anxiety, Alameda Research LLC, and the American Psychological Foundation. He has received royalties from Macmillan Learning and a stipend for editorial duties from the Association for Behavioral and Cognitive Therapies (ABCT). Dr. Fatori has received research support from the Fundação de Amparo à Pesquisa do Estado de São Paulo (grant 2016/13451-9), the Open Society Foundation (grant OR219-62903), and the Grand Challenges Canada & Fundação

Maria Cecilia Souto Vidigal (grant SB-POC-1810-20573). Dr. Freeman has received research funding from the National Institute of Mental Health (NIMH) and PCORI. She has received royalties from Oxford University Press and Guilford Press. She has served on the Scientific and Clinical Advisory Board of the International OCD Foundation (IOCDF). Dr. Geller has received grant or research support from Biohaven Pharmaceuticals, Neurocrine Biosciences, and Teva Pharmaceutical Industries. He has served on the editorial boards of *Comprehensive Psychiatry* and *Annals of Clinical Psychiatry*. He has received honoraria from the American Academy of Child and Adolescent Psychiatry. He has held stock options/ownership in Assurex Health, Revolutionary Road, and Neurocrine Biosciences. He has a Eunice Kennedy Shriver National Institute of Child Health and Human Development subcontract through the Duke Clinical Research Center. Dr. Goodman has received research funding from NIH, Biohaven Pharmaceuticals, and Mater Foundation. He has received honoraria from Biohaven Pharmaceuticals and Neurocrine. Dr. Lenhard has reported being previously employed by Stockholm Healthcare Services and now is currently employed by WeMind Psykiatri. Dr. Lewin has received research support from the Center for Diseases Control and Prevention, the REAM Foundation, and the Tourette Association of America (TAA), from whom he has received speaker honorarium and travel support. He has served as a consultant for Bracket, LLLC and Columbia University – Data Safety and Monitoring Board. He has served on the scientific advisory board for IOCDF and is a member of the American Psychological Association Commission on Accreditation and the Board of Directors of the American Board of Clinical Child and Adolescent Psychology, from whom he has received travel support. He has acknowledged receiving publishing honorarium and associate editor stipend from Springer and Elsevier. Dr. Peris has received research funding from NIMH and PCORI. She has received royalties from Oxford University Press. Dr. Piacentini has received research support from NIMH, PCORI, the TLC Foundation for BFRBs, and Pfizer Pharmaceuticals; publication royalties from Guilford Press and Oxford University Press; and travel/speaking honoraria from the TAA, IOCDF, and the TLC Foundation for BFRBs. Drs. A. I. Rosa-Alcázar and A. Rosa-Alcázar have received research support from the Ministry of Economy and Competitiveness of the Spanish Government (Project PSI2016-78185-P) and the Science Agency and Technology (Seneca Foundation, Region of Murcia, Project 20902/PI/18). These disclosures are unrelated to the current project. Dr. Rozenman has received funding in the last three years from NIMH (R61MH121552) and the University of Denver to conduct research unrelated to the current project. She will have a book published with Oxford's Treatments that Work series and may receive royalties later this year. Dr. Shavitt has received research grants from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ-303754/2018-4) and NIMH (RO1MH113250 subcontract). Dr. Small has received funding from the NIH and book royalties from Cambridge University Press. Dr. Thomsen has received royalties from book Publishers Gyldendal and Dansk Psykologisk Forlag for books on OCD and ADHD. He has received speaker fees within the last 3 years from Medicine and Shire. Dr. Weidle has received royalties from book publishers Gyldendal and Universitetsforlaget for co-authorship of books on OCD and Child and Adolescent Psychiatry. Dr. Miguel has received research support from the Fundação de Amparo à Pesquisa do Estado de São Paulo (grants 2014/50917-0; 2020/06172-1; 2020/00851-4), the Conselho Nacional de Desenvolvimento Científico e Tecnológico (grant CNPQ-465550/2014-2), NIH (R01MH113250-01), and UNICEF (grant 43316196). Dr. Storch has received grant support from NIH, the Ream Foundation, the Greater Houston Community Foundation, IOCDF, ReBuild Texas, and the Texas Higher Education Coordinating Board. He has received book royalties from Elsevier, Springer, the American Psychological Association, Jessica Kingsley, Oxford, Wiley, and Lawrence Erlbaum. He has reported holding stock in NView, where he serves on the clinical advisory board. He has served as a consultant for Levo Therapeutics in the past 3 years, and currently serves as a consultant for Biohaven. Prof. Mataix-Cols has received personal fees from Elsevier for editorial work and royalties for contributing articles to UpToDate, Inc. Dr. Bloch has received grant or research support from Therapix Biosciences, Emalex Biosciences, Neurocrine Biosciences, Janssen Pharmaceuticals, Biohaven Pharmaceuticals, NIH, National Alliance for Research on Schizophrenia and Depression (NARSAD), Lesbian Health Fund, Yale Foundation for Lesbian and Gay Studies (FLAGS), and Patterson Foundation. He has served on the advisory board/data monitoring and safety board of Therapix Biosciences. He has served as associate editor of *Journal of Child Psychology and Psychiatry* and on the editorial boards of *Journal of Child and Adolescent Psychopharmacology* and *Depression and Anxiety*. He has received royalties from Wolters Kluwer for *Lewis's Child and*

*Adolescent Psychiatry: A Comprehensive Textbook, Fifth Edition.* He has received moonlighting pay from the Veteran's Administration. Drs. Artukoglu, Landeros-Weisenberger, Asbahr, Franklin, Grant, Heyman, Ivarsson, Li, Merlo, Mohsenabadi, Sapya, Serlachius, Shabani, Skarphedinnsson, Swedo, Turner, and Mss. Ramakrishnan, Levine, Johnson, Cepeda have reported no biomedical financial interests or potential conflicts of interest.

Correspondence to Michael H. Bloch, MD, MS, Yale Child Study Center, 230 South Frontage Road, Room G34, New Haven, CT 06519; e-mail: michael.bloch@yale.edu

0890-8567/\$36.00/©2021 American Academy of Child and Adolescent Psychiatry

<https://doi.org/10.1016/j.jaac.2021.05.027>

## REFERENCES

- Douglass HM, Moffitt TE, Dar R, McGee R, Silva P. Obsessive-compulsive disorder in a birth cohort of 18-year-olds: prevalence and predictors. *J Am Acad Child Adolesc Psychiatry.* 1995;34:1424-1431. <https://doi.org/10.1097/00004583-199511000-00008>.
- Valleni-Basile LA, Garrison CZ, Jackson KL, *et al.* Frequency of obsessive-compulsive disorder in a community sample of young adolescents. *J Am Acad Child Adolesc Psychiatry.* 1994;33:782-791. <https://doi.org/10.1097/00004583-199407000-00002>.
- Stein DJ, Costa DLC, Lochner C, *et al.* Obsessive-compulsive disorder. *Nat Rev Dis Primers.* 2019;5:52. <https://doi.org/10.1038/s41572-019-0102-3>.
- Scahill L, Riddle MA, McSwiggin-Hardin M, *et al.* Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. *J Am Acad Child Adolesc Psychiatry.* Jun. 1997;36: 844-528. <https://doi.org/10.1097/00004583-199706000-00023>.
- Storch EA, Murphy TK, Geffken GR, *et al.* Psychometric evaluation of the Children's Yale-Brown Obsessive-Compulsive Scale. *Psychiatry Res.* 2004;129:91-98. <https://doi.org/10.1016/j.psychres.2004.06.009>.
- Asbahr FR, Castillo AR, Ito LM, Latorre MR, Moreira MN, Lotufo-Neto F. Group cognitive-behavioral therapy versus sertraline for the treatment of children and adolescents with obsessive-compulsive disorder. *J Am Acad Child Adolesc Psychiatry.* 2005;44: 1128-1136. <https://doi.org/10.1097/01.chi.0000177324.40005.6f>.
- Riddle MA, Reeve EA, Yaryura-Tobias JA, *et al.* Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. *J Am Acad Child Adolesc Psychiatry.* 2001;40:222-229. <https://doi.org/10.1097/00004583-200102000-00017>.
- Geller DA, Wagner KD, Emslie G, *et al.* Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry.* 2004;43:1387-1396. <https://doi.org/10.1097/01.chi.0000138356.29099.fl>.
- Skarphedinnsson G, Weidle B, Thomsen PH, *et al.* Continued cognitive-behavior therapy versus sertraline for children and adolescents with obsessive-compulsive disorder that were non-responders to cognitive-behavior therapy: a randomized controlled trial. *Eur Child Adolesc Psychiatry.* 2015;24:591-602. <https://doi.org/10.1007/s00787-014-0613-0>.
- Geller DA, Hoog SL, Heiligenstein JH, *et al.* Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. *J Am Acad Child Adolesc Psychiatry.* 2001;40:773-779. <https://doi.org/10.1097/00004583-200107000-00011>.
- Fatori D, de Bragança Pereira CA, Asbahr FR, *et al.* Adaptive treatment strategies for children and adolescents with obsessive-compulsive disorder: a sequential multiple assignment randomized trial. *J Anxiety Disord.* 2018;58:42-50. <https://doi.org/10.1016/j.janxdis.2018.07.002>.
- Piacentini J, Bergman RL, Chang S, *et al.* Controlled comparison of family cognitive behavioral therapy and psychoeducation/relaxation training for child obsessive-compulsive disorder. *J Am Acad Child Adolesc Psychiatry.* 2011;50:1149-1161. <https://doi.org/10.1016/j.jaac.2011.08.003>.
- Peris TS, Rozenman MS, Sugar CA, McCracken JT, Piacentini J. Targeted family intervention for complex cases of pediatric obsessive-compulsive disorder: a randomized controlled trial. *J Am Acad Child Adolesc Psychiatry.* 2017;56:1034-1042.e1. <https://doi.org/10.1016/j.jaac.2017.10.008>.
- Storch EA, Wilhelm S, Sprich S, *et al.* Efficacy of augmentation of cognitive behavior therapy with weight-adjusted D-cycloserine vs placebo in pediatric obsessive-compulsive disorder: a randomized clinical trial. *JAMA Psychiatry.* 2016;73:779-788. <https://doi.org/10.1001/jamapsychiatry.2016.1128>.
- Liebowitz MR, Turner SM, Piacentini J, *et al.* Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry.* 2002;41: 1431-1438. <https://doi.org/10.1097/00004583-200212000-00014>.
- Mataix-Cols D, Fernández de la Cruz L, Nordsetten AE, Lenhard F, Isomura K, Simpson HB. Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder. *World Psychiatry.* 2016;15:80-81. <https://doi.org/10.1002/wps.20299>.
- Storch EA, Lewin AB, De Nadai AS, Murphy TK. Defining treatment response and remission in obsessive-compulsive disorder: a signal detection analysis of the Children's Yale-Brown Obsessive Compulsive Scale. *J Am Acad Child Adolesc Psychiatry.* 2010; 49:708-717. <https://doi.org/10.1016/j.jaac.2010.04.005>.
- Skarphedinnsson G, De Nadai AS, Storch EA, Lewin AB, Ivarsson T. Defining cognitive-behavior therapy response and remission in pediatric OCD: a signal detection analysis of the Children's Yale-Brown Obsessive Compulsive Scale. *Eur Child Adolesc Psychiatry.* 2017;26:47-55. <https://doi.org/10.1007/s00787-016-0863-0>.
- Bujang MA, Adnan TH. Requirements for minimum sample size for sensitivity and specificity analysis. *J Clin Diagn Res.* 2016;10:ye01-ye06. <https://doi.org/10.7860/jcdr/2016/18129.8744>.
- Salameh JP, Bossuyt PM, McGrath TA, *et al.* Preferred Reporting Items for Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies (PRISMA-DTA): explanation, elaboration, and checklist. *BMJ.* 2020;370:m2632. <https://doi.org/10.1136/bmj.m2632>.
- McInnes MDF, Moher D, Thombs BD, *et al.* Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: the PRISMA-DTA Statement. *JAMA.* 2018;319:388-396. <https://doi.org/10.1001/jama.2017.19163>.
- Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. *J Consult Clin Psychol.* 1991;59:12-19. <https://doi.org/10.1037//0022-006x.59.1.12>.
- Steinhauser S, Schumacher M, Rücker G. Modelling multiple thresholds in meta-analysis of diagnostic test accuracy studies. *BMC Med Res Methodol.* 2016;16:97. <https://doi.org/10.1186/s12874-016-0196-1>.
- Rücker G, Steinhauser S, Kolampally S, Schwarzer G. diagmeta: meta-Analysis of Diagnostic Accuracy Studies with Several Cutpoints. R package version 04-02020.
- Perkins NJ, Schisterman EF. The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. *Am J Epidemiol.* 2006; 163:670-675. <https://doi.org/10.1093/aje/kwj063>.
- Takwoingi Y, Riley RD, Deeks JJ. Meta-analysis of diagnostic accuracy studies in mental health. *Evid Based Ment Health.* 2015;18:103-109. <https://doi.org/10.1136/eb-2015-102228>.
- van Enst WA, Ochodo E, Scholten RJ, Hooft L, Leeftang MM. Investigation of publication bias in meta-analyses of diagnostic test accuracy: a meta-epidemiological study. *BMC Med Res Methodol.* 2014;14:70. <https://doi.org/10.1186/1471-2288-14-70>.
- Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. *JAMA.* 2004; 292:1969-1976. <https://doi.org/10.1001/jama.292.16.1969>.
- Abedi MR, Vostanis P. Evaluation of quality of life therapy for parents of children with obsessive-compulsive disorders in Iran. *Eur Child Adolesc Psychiatry.* 2010;19:605-613. <https://doi.org/10.1007/s00787-010-0098-4>.
- Alaghband-Rad J, Hakimshooshtary M. A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD). *Eur Child Adolesc Psychiatry.* 2009;18:131-135. <https://doi.org/10.1007/s00787-007-0634-z>.
- Barrett P, Healy-Farrell L, March JS. Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: a controlled trial. *J Am Acad Child Adolesc Psychiatry.* 2004;43:46-62. <https://doi.org/10.1097/00004583-200401000-00014>.
- Bolton D, Perrin S. Evaluation of exposure with response-prevention for obsessive compulsive disorder in childhood and adolescence. *J Behav Ther Exp Psychiatry.* 2008; 39:11-22. <https://doi.org/10.1016/j.jbtep.2006.11.002>.
- Bolton D, Williams T, Perrin S, *et al.* Randomized controlled trial of full and brief cognitive-behaviour therapy and wait-list for paediatric obsessive-compulsive disorder. *J Child Psychol Psychiatry.* 2011;52:1269-1278. <https://doi.org/10.1111/j.1469-7610.2011.02419.x>.
- Comer JS, Furr JM, Kerns CE, *et al.* Internet-delivered, family-based treatment for early-onset OCD: a pilot randomized trial. *J Consult Clin Psychol.* 2017;85:178-186. <https://doi.org/10.1037/ccp0000155>.
- de Haan E, Hoogduin KA, Buitelaar JK, Keijsers GP. Behavior therapy versus clomipramine for the treatment of obsessive-compulsive disorder in children and adolescents. *J Am Acad Child Adolesc Psychiatry.* 1998;37:1022-1029. <https://doi.org/10.1097/00004583-199810000-00011>.
- DeVaugh-Geiss J, Moroz G, Biederman J, *et al.* Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder—a multicenter trial. *J Am Acad Child Adolesc Psychiatry.* 1992;31:45-49. <https://doi.org/10.1097/00004583-199201000-00008>.

37. Farrell LJ, Waters AM, Boschen MJ, *et al.* Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy. *Depress Anxiety*. 2013;30:723-731. <https://doi.org/10.1002/da.22132>.
38. Franklin ME, Sapyta J, Freeman JB, *et al.* Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial. *JAMA*. 2011;306:1224-1232. <https://doi.org/10.1001/jama.2011.1344>.
39. Freeman J, Sapyta J, García A, *et al.* Family-based treatment of early childhood obsessive-compulsive disorder: the Pediatric Obsessive-Compulsive Disorder Treatment Study for Young Children (POTS Jr)—a randomized clinical trial. *JAMA Psychiatry*. 2014;71:689-698. <https://doi.org/10.1001/jamapsychiatry.2014.170>.
40. Freeman JB, García AM, Coyne L, *et al.* Early childhood OCD: preliminary findings from a family-based cognitive-behavioral approach. *J Am Acad Child Adolesc Psychiatry*. 2008;47:593-602. <https://doi.org/10.1097/CHI.0b013e31816765f9>.
41. Grant PJ, Joseph LA, Farmer CA, *et al.* 12-Week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder. *Neuropsychopharmacology*. 2014;39:1453-1459. <https://doi.org/10.1038/npp.2013.343>.
42. Lenhard F, Andersson E, Mataix-Cols D, *et al.* Therapist-guided, internet-delivered cognitive-behavioral therapy for adolescents with obsessive-compulsive disorder: a randomized controlled trial. *J Am Acad Child Adolesc Psychiatry*. 2017;56:10-19. <https://doi.org/10.1016/j.jaac.2016.09.515>.
43. Lewin AB, Park JM, Jones AM, *et al.* Family-based exposure and response prevention therapy for preschool-aged children with obsessive-compulsive disorder: a pilot randomized controlled trial. *Behav Res Ther*. 2014;56:30-38. <https://doi.org/10.1016/j.brat.2014.02.001>.
44. Li F, Welling MC, Johnson JA, *et al.* N-acetylcysteine for pediatric obsessive-compulsive disorder: a small pilot study. *J Child Adolesc Psychopharmacol*. 2020;30:32-37. <https://doi.org/10.1089/cap.2019.0041>.
45. March JS, Biederman J, Wolkow R, *et al.* Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. *JAMA*. 1998;280:1752-1756. <https://doi.org/10.1001/jama.280.20.1752>.
46. Mataix-Cols D, Turner C, Monzani B, *et al.* Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: pilot randomised controlled trial. *Br J Psychiatry*. 2014;204:77-78. <https://doi.org/10.1192/bjp.bp.113.126284>.
47. Merlo LJ, Storch EA, Lehmkuhl HD, *et al.* Cognitive behavioral therapy plus motivational interviewing improves outcome for pediatric obsessive-compulsive disorder: a preliminary study. *Cogn Behav Ther*. 2010;39:24-27. <https://doi.org/10.1080/16506070902831773>.
48. Neziroglu F, Yaryura-Tobias JA, Walz J, McKay D. The effect of fluvoxamine and behavior therapy on children and adolescents with obsessive-compulsive disorder. *J Child Adolesc Psychopharmacol*. 2000;10:295-306. <https://doi.org/10.1089/cap.2000.10.295>.
49. O'Neill J, Piacentini J, Chang S, *et al.* Glutamate in pediatric obsessive-compulsive disorder and response to cognitive-behavioral therapy: randomized clinical trial. *Neuropsychopharmacology*. 2017;42:2414-2422. <https://doi.org/10.1038/npp.2017.77>.
50. Reynolds SA, Clark S, Smith H, *et al.* Randomized controlled trial of parent-enhanced CBT compared with individual CBT for obsessive-compulsive disorder in young people. *J Consult Clin Psychol*. 2013;81:1021-1026. <https://doi.org/10.1037/a0034429>.
51. Rosa-Alcázar Á, Rosa-Alcázar AI, Olivares-Olivares PJ, Parada-Navas JL, Rosa-Alcázar E, Sánchez-Meca J. Family involvement and treatment for young children with obsessive-compulsive disorder: randomized control study. *Int J Clin Health Psychol*. 2019;19:218-227. <https://doi.org/10.1016/j.ijchp.2019.06.001>.
52. Shabani MJ, Mohsenabadi H, Omidi A, *et al.* An Iranian study of group acceptance and commitment therapy versus group cognitive behavioral therapy for adolescents with obsessive-compulsive disorder on an optimal dose of selective serotonin reuptake inhibitors. *J Obsessive-Compulsive Relat Disord*. 2019/07/01/ 2019;22:100440. <https://doi.org/10.1016/j.jocrd.2019.04.003>
53. Storch EA, Bussing R, Small BJ, *et al.* Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive-compulsive disorder. *Behav Res Ther*. 2013;51:823-829. <https://doi.org/10.1016/j.brat.2013.09.007>.
54. Storch EA, Caporino NE, Morgan JR, *et al.* Preliminary investigation of web-camera delivered cognitive-behavioral therapy for youth with obsessive-compulsive disorder. *Psychiatry Res*. 2011;189:407-412. <https://doi.org/10.1016/j.psychres.2011.05.047>.
55. Storch EA, Geffken GR, Merlo LJ, *et al.* Family-based cognitive-behavioral therapy for pediatric obsessive-compulsive disorder: comparison of intensive and weekly approaches. *J Am Acad Child Adolesc Psychiatry*. 2007;46:469-478. <https://doi.org/10.1097/chi.0b013e31803062e7>.
56. Storch EA, Murphy TK, Goodman WK, *et al.* A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. *Biol Psychiatry*. 2010;68:1073-1076. <https://doi.org/10.1016/j.biopsych.2010.07.015>.
57. Turner CM, Mataix-Cols D, Lovell K, *et al.* Telephone cognitive-behavioral therapy for adolescents with obsessive-compulsive disorder: a randomized controlled non-inferiority trial. *J Am Acad Child Adolesc Psychiatry*. 2014;53:1298-1307.e2. <https://doi.org/10.1016/j.jaac.2014.09.012>.
58. Williams TI, Salkovskis PM, Forrester L, Turner S, White H, Allsopp MA. A randomised controlled trial of cognitive behavioural treatment for obsessive compulsive disorder in children and adolescents. *Eur Child Adolesc Psychiatry*. 2010;19:449-456. <https://doi.org/10.1007/s00787-009-0077-9>.
59. Wolters LH, de Haan E, Hogendoorn SM, Boer F, Prins PJM. Severe pediatric obsessive compulsive disorder and co-morbid autistic symptoms: effectiveness of cognitive behavioral therapy. *J Obsessive-Compulsive Relat Disord*. 2016;10:69-77. <https://doi.org/10.1016/j.jocrd.2016.06.002>.
60. Altman DG, Royston P. The cost of dichotomising continuous variables. *BMJ*. 2006;332:1080. <https://doi.org/10.1136/bmj.332.7549.1080>.
61. Streiner DL. Breaking up is hard to do: the heartbreak of dichotomizing continuous data. *Can J Psychiatry*. 2002;47:262-266. <https://doi.org/10.1177/070674370204700307>.
62. Samara MT, Spinelli LM, Furukawa TA, *et al.* Imputation of response rates from means and standard deviations in schizophrenia. *Schizophr Res*. 2013;151:209-214. <https://doi.org/10.1016/j.schres.2013.10.029>.
63. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. *Psychiatry (Edgmont)*. 2007;4:28-37.
64. Riddle MA, Scahill L, King RA, *et al.* Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. *J Am Acad Child Adolesc Psychiatry*. 1992;31:1062-1069. <https://doi.org/10.1097/00004583-199211000-00011>.
65. Tudur Smith C, Marcucci M, Nolan SJ, *et al.* Individual participant data meta-analyses compared with meta-analyses based on aggregate data. *Cochrane Database Syst Rev*. 2016;9:Mr000007. <https://doi.org/10.1002/14651858.MR000007.pub3>.